Table 4 Logistic regression models predicting PD-L1 cancer expression by IHC stains

From: Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer

 

Crude odds ratio (95% CI)

Adjusted odds ratio a (95% CI)

5-year change in age at diagnosis

0.98 (0.83–1.1)

 

Histology

 Ductal versus mixed

11.4 (0.60–214.6)

 

Tumor grade

 3 vs. 1/2

0.72 (0.21–2.5)

 

Lymphovascular invasion

 Present versus absent

0.40 (0.19–0.85)

0.41 (0.18–0.92)

Lymphocytic infiltrate

 Positive/focally positive versus negative

3.1 (1.0–9.4)

3.3 (1.1–10.4)

EGFR

 Positive versus negative

1.6 (0.71–3.6)

 

Cytokeratin 5/6

 Positive versus negative

1.0 (0.53–2.0)

 

Cytokeratin 14

 Positive versus negative

0.93 (0.49–1.8)

 

Androgen receptor

1% vs. <1%

2.7 (1.3–5.9)

3.2 (1.4–7.5)

  1. Abbreviation: IHC, immunohistochemical.
  2. aAdjusted for all other variables that were significantly associated with PD-L1 cancer.